CytomX Therapeutics prices USD 250 million follow-on stock offering at USD 5.3 per share

CytomX Therapeutics, Inc. -0.41%

CytomX Therapeutics, Inc.

CTMX

4.87

-0.41%

CytomX priced an underwritten public offering of 45.99 million common shares at USD 5.3 per share. The offering also includes pre-funded warrants to purchase 1.18 million common shares, with expected gross proceeds of USD 250 million. CytomX granted underwriters a 30-day option to buy up to 7.08 million additional common shares. The company said it plans to use the net proceeds to fund development of Varseta-M and other pipeline programs, and for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603172246PRIMZONEFULLFEED9674201) on March 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.